2m 2m 2m 2m 2m 2m 2m
LB PHARM (LBRX)
NASDAQ
$30.62+$0.75 (+2.51%)
Price as of Jun 23, 2026 4:46 PM EDT- $856.6MMarket Cap
- N/A1-Year Change
- BiotechnologyIndustry
LB PHARM (LBRX)
$30.62+$0.75 (+2.51%)
Annual
Quarterly
12/31/2025 | ||
|---|---|---|
Income Statement | ||
Total Operating Revenue | N/A N/A | |
Cost of Revenue | N/A N/A | |
Gross Profit | 0 N/A | |
Sales and Marketing Expense | N/A N/A | |
Research and Development Expense | -16.7M N/A | |
Depreciation and Amortization Expense | 321,000 N/A | |
Total Operating Expenses | 30.4M N/A | |
Operating Profit | -25.2M N/A | |
Interest Income | 3.9M N/A | |
Interest Expense | N/A N/A | |
Interest Income and Expense and Net | 3.9M N/A | |
Total Nonoperating Income and Expense | 5.2M N/A | |
Income before Taxes | -25.2M N/A | |
Income Taxes | 1,000 N/A | |
Extraordinary Items | N/A N/A | |
Net Income | -25.2M N/A | |
Net Income from Continuing Operations Applicable to Common | -25.2M N/A | |
Basic EPS and Net Income | -3.13 N/A | |
Diluted EPS and Net Income | -3.13 N/A | |
Basic Weighted Average Shares | 8.0M N/A | |
Diluted Weighted Average Shares | 8.0M N/A | |
Balance Sheet | ||
Cash and Cash Equivalents | 250.2M N/A | |
Short-Term Investments | 45.0M N/A | |
Cash and Cash Equivalents and Short-Term Investments | 295.2M N/A | |
Total Current Assets | 308.4M N/A | |
Accumulated Depreciation | 420,000 N/A | |
Property and Plant and Equipment and Net | 1.6M N/A | |
Total Long-Term Assets | 1.6M N/A | |
Total Assets | 312.9M N/A | |
Income Taxes Payable | N/A N/A | |
Total Short-Term Debt | N/A N/A | |
Total Current Liabilities | 7.4M N/A | |
Total Long-Term Debt | N/A N/A | |
Total Long-Term Liabilities | 4.2M N/A | |
Total Liabilities | 11.6M N/A | |
Retained Earnings | -129.5M N/A | |
Total Stockholders Equity | 301.3M N/A | |
Total Shares Outstanding | 25.3M N/A | |
Cash Flow | ||
Cash from Operating Activities | -35.2M N/A | |
Capital Expenditures | 52,000 N/A | |
Cash from Investing Activities | -39.9M N/A | |
Dividends Paid | N/A N/A | |
Cash from Financing Activities | 302.6M N/A | |
Financials Ratio | ||
Gross Margin | N/A N/A | |
Operating Margin | N/A N/A | |
Return on Assets | N/A N/A | |
Return on Equity | N/A N/A | |
Revenue Growth | N/A N/A | |
Current Ratio | N/A N/A | |
Cash Ratio | N/A N/A | |
Debt-to-Equity Ratio | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow